• Non-binding term sheet with leading Middle Eastern pharmaceutical company
• HREC approval to advance Phase 3 trial for DFIs
• Successful regulatory inspection for Phase 3 clinical trial in Indonesia
• A$4.0 million raised via institutional placement
• Launched Share Purchase Plan for eligible shareholders

Recce Pharmaceuticals Ltd, a developer of synthetic anti-infectives, released its Q4 FY2026 results and operational highlights. The company signed a non-binding term sheet with a leading Middle Eastern pharmaceutical company for an exclusive licensing arrangement covering the commercial sales and distribution of R327 Topical Gel (R327G) for the treatment of Diabetic Foot Infections (DFIs) across the MENA region. Recce also received HREC approval to advance its Phase 3 clinical trial of R327G in Australia for DFIs. The Indonesian National Agency of Drug and Food Control completed a successful regulatory inspection of a Phase 3 clinical trial site in Indonesia. Recce raised A$4.0 million via an institutional placement and launched a Share Purchase Plan for eligible shareholders. The company ended the quarter with a cash balance of AUD $2.9 million and expects to achieve upcoming Phase 3 clinical trial milestones.

Recce expects to achieve upcoming Phase 3 clinical trial milestones

Recce remains focused on executing multiple value-driving initiatives across its clinical and commercial programs, with key near-term priorities including advancing its Registrational Phase 3 clinical trials and progressing discussions towards a definitive licensing agreement.